[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urinary-incontinence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urinary-incontinence":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,81,0,25,[9,43,65,94,128,156,177,206,236,260,290,316,339,366,393,421,448,477,501,531,558,582,609,635,659],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100631468","phase-4-prophylactic-antibiotics-for-outpatient-urethral-bulking-100631468",false,"NCT07501065","Prophylactic Antibiotics for Outpatient Urethral Bulking","Prophylactic Antibiotics for Outpatient Urethral Bulking: Impact on Post-Procedural Urinary Tract Infection Rates","Inclusion Criteria:\n\n* Women ≥ 18 years of age.\n* Patients evaluated by a pelvic floor specialist (either urogynecologist or urologist) at the University of Miami with plans to undergo urethral bulking with Bulkamid for stress urinary incontinence or mixed urinary incontinence (stress predominant).\n* Negative testing for UTI in pre-procedural work-up, including either negative urine culture or urine dip negative for infection (infection is defined as the presence of nitrites and\u002For pyuria with \\>1+ leukocyte esterase on dipstick or \\>5 WBC\u002FHPF).\n* Post-void residual volume of 150 mL or less (measured by either catheterization or bladder scan) before the procedure\n* Fluent in English or Spanish\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Contraindications to both oral antibiotics including antibiotic allergies or significant renal disease (GFR \\\u003C30)\n* Patient undergoing additional pelvic organ prolapse procedures or other urologic procedures concomitantly that also involve insertion \\[KB2.1\\]of a foreign object\n* Recurrent UTIs, defined as 3 or more UTIs within the past 12 months or 2 UTIs within the past 6 months\n* Patients currently taking daily antibiotic prophylaxis for any reason\n* Patients with immunosuppression due to underlying medical conditions\n* Patients who are pregnant\n* Recent antibiotic treatment within one week of the procedure\n* Unable or unwilling to provide informed consent or complete study procedures","FEMALE","18 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The purpose of this study is to evaluate whether taking prophylactic (preventative) antibiotics at the time of standard of care clinic-based urethral bulking reduces the risk of post-procedural urinary tract infection (UTI).",[27,28,29],"Urinary Tract Infections","Stress Urinary Incontinence","Urinary Incontinence","RECRUITING","2026-08-18",{"date":33,"type":34},"2026-08-20","ACTUAL",{"date":36,"type":21},"2026-08",{"date":38,"type":21},"2028-12",{"name":40,"class":41},"University of Miami","OTHER",2,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":60,"leadSponsor":62,"locationsCount":64},"100646280","improving-uroflowmetry-interpretability-evaluating-the-impact-of-patient-reminder-systems-100646280","NCT07692789","Improving Uroflowmetry Interpretability: Evaluating the Impact of Patient Reminder Systems","Inclusion Criteria\n\n1. Age 18 years or older\n2. Sex assigned at birth: Female.\n3. English-speaking\n4. Scheduled to undergo a urodynamics study at the OSU Upper Arlington Outpatient Clinic, OSU New Albany Outpatient Clinic, or OSU Eye and Ear Institute\n5. Ability to access a telephone\n6. Active MyChart account\n7. Ability to provide informed consent\n8. Documented post-residual volume of less than 150 mL\n9. Ability to be reached by telephone after three call attempts\n10. Negative point-of-care urinary tract infection on the day of the scheduled procedure (SOC)\n\nExclusion criteria:\n\n1. Under 18 years of age\n2. Patients with structural causes of urinary retention\u002Fincomplete bladder emptying (defined as a post-void residual \\>150ml) or a positive point-of-care urinary tract infection on the day of the procedure.\n3. Men are excluded as the population of interest is the female urogynecology population in both urology and obstetrics and gynecology.\n4. Patients without access to a telephone or an active MyChart account are excluded because the intervention relies on telephone calls and electronic messaging for delivery of pre-procedure education and reminders.\n5. Individuals who cannot be reached by telephone are excluded because they cannot receive the intervention.\n6. Non-English speaking individuals are excluded because they will not be able to receive the standardized phone call in English and will not be able to complete the informed consent.",{"count":50,"type":21},162,[52],"NA","The purpose of this study is to evaluate the impact of pre-procedure patient reminder systems on patient satisfaction, preparedness, and anxiety among patients undergoing urodynamics studies. The rate of successful procedure completion will be compared between a prospective intervention group and a historical control group to determine whether the intervention improves procedural success and healthcare delivery.",[55,29],"Pelvic Organ Prolapse","2026-08-13",{"date":58,"type":34},"2026-08-17",{"date":36,"type":21},{"date":61,"type":21},"2027-12",{"name":63,"class":41},"Ohio State University",1,{"id":66,"slug":67,"hasResults":12,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":12,"sex":73,"minAge":18,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":90,"leadSponsor":92,"locationsCount":64},"100646916","rehabilitation-and-sex-therapy-to-optimize-recovery-after-prostate-cancer-treatment-100646916","NCT07685249","Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment","RESTORE-PC: Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment: A Randomized Feasibility Trial","RESTORE-PC","Inclusion Criteria\n\n* Age 18 years or older.\n* Biopsy-confirmed localized prostate adenocarcinoma.\n* Treated with nerve-sparing radical prostatectomy, radiotherapy, or cryoablation as primary index therapy for prostate cancer at Duke Health.\n* Initiating pelvic floor physical therapy as part of routine clinical care.\n* Pre-treatment International Index of Erectile Function-5 (IIEF-5) score meeting the eligibility threshold, with or without aids, determined by medical record chart review (when documented within 4 months prior to index treatment) or collected post-treatment with participant recall anchored to the month prior to treatment. Eligibility threshold for the IIEF-5 is at or above 17.\n* Able to read and understand English to complete patient-reported outcome measures.\n* Ability to provide informed consent.\n\nExclusion Criteria\n\n* Any androgen deprivation therapy (ADT) given for prostate cancer treatment or planned during the intervention or follow-up period, including neoadjuvant, concurrent, or adjuvant ADT.\n* Recieved non-nerve-sparing treatment (when applicable).\n* Unable to engage in pelvic floor physical therapy or penile rehabilitation protocol.\n* Need for additional or secondary prostate cancer treatment during the intervention period.\n* Documented cognitive impairment or impairment that would interfere with participation.\n* Major psychiatric concern that would interfere with ability to consent or participate, such as schizophrenia, based on the medical record or treating clinician assessment.\n* Inability to complete study video visits or questionnaires.\n* History of prior local or systemic treatment for prostate cancer","MALE",{"count":75,"type":21},30,[52],"This study is being done at Duke Health and includes adult men who have been treated for localized prostate cancer. The goal is to see if it is feasible and acceptable to offer sex therapy by telehealth after prostate cancer treatment.\n\nAll participants receive pelvic floor physical therapy and education about penile rehabilitation, including use of a vacuum erection device. Participants are randomly assigned to one of two groups. One group receives pelvic floor physical therapy plus telehealth sex therapy, with about ten sessions over six months. The other group receives pelvic floor physical therapy alone.\n\nParticipants complete questionnaires about urinary and sexual health at the start of the study and over the next two years. Short interviews are also done at 6 and 12 months. Medicines for erectile function are prescribed as part of usual clinical care and are not part of the study treatment.",[79,29,80],"Prostate Cancer","Erectile Dysfunction",[82,83,84],"Pelvic Floor Physical Therapy","Sex Therapy","Penile Rehabilitation","NOT_YET_RECRUITING","2026-08-05",{"date":88,"type":34},"2026-08-07",{"date":36,"type":21},{"date":91,"type":21},"2028-08",{"name":93,"class":41},"Duke University",{"id":95,"slug":96,"hasResults":12,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":12,"sex":73,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":107,"conditions":108,"keywords":115,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":126,"locationsCount":64},"100549884","study-of-the-quality-of-life-in-school-aged-children-with-posterior-urethral-valves-100549884","NCT06439862","Study of the Quality of Life in School Aged-children With Posterior Urethral Valves","Quality of Life in School Aged-children With Posterior Urethral Valves","QUALIVUP","Inclusion Criteria:\n\n* Male patients and their parents\u002Frelatives\n* Aged 6 to 17 years old\n* Treated for PUV in their first year of life between 2006 and 2018\n* Managed in the Femme-Mère-Enfant Hospital in Lyon\n\nExclusion Criteria:\n\n* Children with pre-existing severe cognitive and physical disability (physician's rating) from other condition\n* Children enable to complete QoL questionnaire due to mental or communication impairment","6 Years","17 Years",{"count":105,"type":21},300,"OBSERVATIONAL","Posterior urethral valves (PUV) are the most common congenital obstructive lesion of the urethra, affecting from 1 per 3000 to 1 per 8000 live births. Valve ablation usually resolves the obstruction in PUV but patients still may suffer of deterioration in renal and urinary functions.\n\nRenal insufficiency is the most feared long-term complication. Up to 50 % of the patients will develop chronic kidney disease (CKD), and up to 20 % will develop end-stage renal disease (ESRD) and ultimately will require kidney transplantation. PUV is the first urological cause of ESRD. Progression towards CKD depends on febrile urinary tract infections (UTIs), severity of a vesicoureteral reflux and bladder dysfunction.\n\nBladder dysfunction is due to an overactive and small poorly compliant bladder during infancy. Detrusor overactivity usually decreases in childhood and bladder capacity increases. The most common symptom of this bladder dysfunction is urinary incontinence. 60 % of children are continent at the age of 5 years old and 90 % at 10 years old. In case of persistent bladder dysfunction, medical treatment (anticholinergics, alpha-blockers) may be introduced, or even intermittent catheterizations.\n\nCurrent scientific literature has very few studies on quality of life (QoL) in patients with PUV, mostly in adult patients and very small cohorts. Men treated for PUV in childhood had a good quality of life compared to the normative population, except for sleeping, eating and sexual activity. It seemed that the more severe the urological and nephrological functions were, the lower the QoL was. Children were only asked about intermittent urinary catheterization, and family point of view has never been collected. However, QoL and long-term evolution represent the first concerns of parents-to-be in prenatal counseling, or after diagnosis in an infant with PUV.\n\nHence, the aim of the study is to investigate the quality of life in school-aged children who had been treated for PUV in their first year of life, as measured by the Pediatric Quality of Life Inventory Version 4.0 (PedsQL 4.0).",[109,110,111,112,113,114,29],"Quality of Life","Posterior Urethral Valve","Renal Insufficiency","Chronic Renal Disease","End Stage Renal Disease","Bladder Dysfunction",[116,117,118,119,120],"Quality of life","Posterior Urethral Valves","Children","Adolescents","Family","2026-08-03",{"date":86,"type":34},{"date":124,"type":34},"2024-08-20",{"date":91,"type":21},{"name":127,"class":41},"Hospices Civils de Lyon",{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":139,"conditions":140,"keywords":143,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":152,"leadSponsor":154,"locationsCount":64},"100649769","does-use-of-a-pre-procedure-educational-video-for-urodynamic-testing-reduces-anxiety-100649769","NCT07740629","Does Use of a Pre-Procedure Educational Video for Urodynamic Testing Reduces Anxiety?","Use of a Pre-Procedure Educational Video for Urodynamic Testing as a Tool to Reduce Anxiety: A Prospective Randomized Study","VIDEO-U","Inclusion Criteria:\n\n* women 18 years and above, undergoing a urodynamics test\n\nExclusion Criteria:\n\n* women under SSRI\u002FSNRI treatment women with a known anxiety disorder women who had a previous urodynamics test",{"count":137,"type":21},60,[52],"The objective of this randomized prospective study is to evaluate whether viewing an educational video before urodynamic testing reduces anxiety among women undergoing evaluation for pelvic floor or urinary symptoms.\n\nThe primary research question is: Does viewing a short educational video before urodynamic testing reduce objective and subjective anxiety levels and improve the overall testing experience? Participants scheduled to undergo urodynamic testing as part of routine clinical care will be randomly assigned to either an educational video intervention or standard pre-procedure counseling alone. Participants will complete brief questionnaires, provide saliva samples for cortisol measurement as an objective biomarker of stress, and report anxiety and pain levels before, during, and after urodynamic testing.",[29,141,142],"Urinary Bladder Overactive","Urinary Incontinence , Stress",[144,145,146,147],"Urinary Incontinence, Urodymanics","Video","Stress","Cortisol","2026-08-01",{"date":150,"type":34},"2026-08-04",{"date":148,"type":34},{"date":153,"type":21},"2027-05-01",{"name":155,"class":41},"Yair Daykan",{"id":157,"slug":158,"hasResults":12,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":163,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":165,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":175,"locationsCount":64},"100523350","improving-overactive-bladder-treatment-access-and-adherence-100523350","NCT06094543","Improving Overactive Bladder Treatment Access and Adherence","Improving Overactive Bladder Treatment Access and Adherence Through Personalized Behavioral Modifications and Mobile Technology-Based Interventions","Inclusion Criteria:\n\n* Female aged 18 years or older\n* OAB symptoms for at least 3 months\n* English\u002FSpanish language skills and cognitive status sufficient to complete all study related materials\n* Behavioral treatment naïve patients\n* Previously treated OAB patients without supervised pelvic floor physical therapy or pharmacotherapy within 1 year\n\nExclusion Criteria:\n\n* Post void residual urine \\> 150ml\n* Confirmed diagnosis of Interstitial Cystitis\u002FPainful Bladder Syndrome (IC\u002FPBS)\n* Pregnant or breastfeeding patients\n* Patients residing in a nursing home\n* Comorbid neurological conditions, including spinal cord injury, progressive neurologic illnesses (e.g. Multiple Sclerosis, Parkinson's disease) or central nervous system disease (e.g. brain tumor, stroke)\n* Stage 2 or greater pelvic organ prolapse\n* Any history of urethral stricture\n* Any history of pelvic irradiation\n* Any history of bladder malignancy\n* Current symptomatic urinary tract infection (UTI), unresolved by the time of enrollment\n* Hematuria without a clinical evaluation\n* History or current use of indwelling urinary foley catheterization, suprapubic tube or intermittent catheterization\n* Patients with UI treated with onabotulinumtoxinA, sacral neuromodulation, or percutaneous tibial nerve stimulation (third line therapies)",true,{"count":75,"type":21},[52],"Overactive bladder (OAB) and urinary incontinence (UI) are chronic debilitating and embarrassing conditions that affect 33 million Americans. Yet, both are underdiagnosed and undertreated with significant financial and health-related consequences. OAB syndrome is characterized by urinary urgency, with and without urinary incontinence, urinary frequency, and nocturia. Evidence-based treatments are available, including behavioral therapy, pharmacotherapy, and minimally invasive procedures. Diagnosis and treatment are also associated with improvement in urinary symptoms and overall quality of life (QOL).3 However, 70-80% of treated patients will discontinue use of therapy in the first year due to one of several factors (e.g., cost, tolerability, inadequate effect). In addition, only 4.7% progress to advanced therapies suggesting undertreatment for those that need it most. Vulnerable populations are especially at risk, as therapy utilization are lowest among older, lower income, and\u002For minority groups. Poor access, insufficient patient education regarding disease chronicity, expected outcomes, costs, and potential side effects lead to unrealistic patient perceptions about therapy. This leads to suboptimal therapy duration, poor treatment efficacy, adherence, and undertreatment. The study aims to evaluate a tailored patient-centered tool to begin the treatment process.",[168,29],"Overactive Bladder Syndrome","2026-07-18",{"date":171,"type":34},"2026-07-21",{"date":173,"type":34},"2024-11-01",{"date":61,"type":21},{"name":176,"class":41},"Stanford University",{"id":178,"slug":179,"hasResults":12,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":12,"sex":73,"minAge":184,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":188,"conditions":189,"keywords":191,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":64},"100494518","effect-of-group-preoperative-pelvic-floor-training-for-holep-100494518","NCT05719220","Effect of Group Preoperative Pelvic Floor Training for HoLEP","The Effect of Group Preoperative Pelvic Floor Training on Transient Urinary Incontinence After Holmium Laser Enucleation of the Prostate: A Prospective Cohort Study","Inclusion Criteria:\n\n* Consecutive patients with a diagnosis of BPH with a plan to undergo HoLEP.\n* Between the age of 50-90.\n* Ability to understand and provide informed consent.\n\nExclusion Criteria:\n\n* Patients whom inability to carry out PFT protocol.\n* Patients unwilling or unable to complete follow up care.\n* Severe urinary incontinence due to a history of neurological diseases such as a cerebrovascular accident or spinal cord injuries.\n* Patients whom inability to read and understand the English language.","50 Years","90 Years",{"count":187,"type":21},100,"The main goal of this study is to see if group pelvic floor training before surgery can help prevent urinary incontinence after Holmium laser enucleation of the prostate (HoLEP) surgery. The study has the potential to inform preoperative intervention strategies for managing incontinence after HoLEP.",[190,29],"BPH",[192,193,194,195,196],"benign prostatic hyperplasia","pelvic floor training","group therapy","holmium laser enucleation of the prostate","urinary incontinence","2026-07-15",{"date":199,"type":34},"2026-07-17",{"date":201,"type":34},"2024-02-07",{"date":203,"type":21},"2028-12-01",{"name":205,"class":41},"University of California, San Francisco",{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":163,"sex":214,"minAge":18,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":22,"phases":217,"briefSummary":218,"conditions":219,"keywords":222,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":4},"100645644","effect-of-music-and-lighting-on-anxiety-during-urodynamic-study-100645644","NCT07695324","Effect of Music and Lighting on Anxiety During Urodynamic Study","Effect of Environmental Factors on Patient Anxiety During Urodynamic Study: A Prospective Randomized Trial","CALM-UDS","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Scheduled to undergo urodynamic study (UDS) for clinical indications.\n* Persistent lower urinary tract symptoms despite previous medical treatment or surgery.\n* Able to understand the study procedures and complete the State-Trait Anxiety Inventory (STAI).\n* Provided written informed consent.\n\nExclusion Criteria:\n\n* Use of anxiolytic medications.\n* Use of antiarrhythmic medications.\n* Use of antihypertensive medications.\n* Visual or hearing impairment that could interfere with the environmental interventions or completion of the questionnaire.\n* Refusal or inability to complete the STAI questionnaire.\n* Inability or unwillingness to provide informed consent.","ALL",{"count":216,"type":21},220,[52],"This study is designed to evaluate the effects of environmental modifications, specifically music and lighting conditions, on anxiety in patients undergoing urodynamic study (UDS). Approximately 220 adult participants are planned to be randomly assigned to one of four intervention groups. Anxiety levels before and after the procedure will be assessed using the State-Trait Anxiety Inventory (STAI). The study aims to determine the independent and combined effects of music and lighting on patient anxiety during UDS.",[220,29,221],"Lower Urinary Tract Symptoms","Voiding Dysfunction",[223,224,225,226],"Urodynamics","Anxiety","music","Lighting","2026-07-11",{"date":229,"type":34},"2026-07-14",{"date":231,"type":21},"2026-07-06",{"date":233,"type":21},"2026-09-07",{"name":235,"class":41},"Baskent University Ankara Hospital",{"id":237,"slug":238,"hasResults":12,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":245,"conditions":246,"keywords":247,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":259},"100635658","uk-purewick-at-home-pilot-study-100635658","NCT07555548","UK PureWick™ At-Home Pilot Study","An Open-label Pilot Study Conducted in the UK to Evaluate the Clinical Benefits of the PureWick™ Female External Catheter System Compared to Indwelling Urinary Catheters in Female Patients Receiving Home-based Care","Inclusion Criteria:\n\n1. Adult Female Subjects \\>18 years of age at the time of signing the informed consent.\n2. Treated with indwelling catheters for at least four weeks\n3. Encountered \"problematic catheters\" necessitating a minimum of five interventions within the past month, involving medical treatment and HCP consultation;\n4. Willing to comply with all study procedures in this protocol\n5. The subject (or subject's power of attorney) must be willing and able to read, understand, sign, and date the informed consent form.\n\nExclusion Criteria:\n\nSubjects are excluded from the study if any of the following criteria apply:\n\n1. Has frequent episodes of bowel incontinence without a fecal management system in place; or\n2. Has moderate to heavy menstruation and cannot use a tampon or menstrual cup; or\n3. Has vaginal or other chronic non-urinary tract infections (UTIs), active genital herpes; or\n4. Is agitated, combative, and\u002For uncooperative and may remove the external catheter; or\n5. Has any wound, open lesion or irritation on the genitalia, perineum, or sacrum; or\n6. Has any pre-existing neurological, psychiatric, or other conditions that would confound quality of life assessment or would make it difficult to self-report on quality-of-life questionnaires in the opinion of the investigator; or\n7. Is known to be pregnant at time of enrollment (for women of childbearing age); or\n8. Has a confirmed diagnosis of urinary tract infection at the time of enrollment.\n9. Subjects with a urine output of ≥1800 mL over a 12-hour period who, or whose caregivers, are unable to independently empty the collection canister.\n10. Any other condition that, in the opinion of the investigator, would preclude them from participating in the study.",{"count":244,"type":21},95,"The UK PureWick™ At-Home Study is being carried out to see how well the PureWick™ Collection System works for women who use it at home instead of a traditional catheter. Traditional catheters are placed inside the body. The PureWick™ Collection System is different, it's placed outside the body .\n\nIn this study, researchers want to find out: how effective the PureWick™ Collection System is in helping women manage urine collection at home, whether patients prefer using PureWick™ Collection System over the usual catheter, how it affects their sleep, and overall well-being.The PureWick™ Collection System is intended for the treatment of patients who leak urine (called urine incontinence). The PureWick™ Collection System is designed to help manage urine in female patients without needing to insert a urinary catheter into the body.",[29],[248],"UTI","2026-07-10",{"date":251,"type":34},"2026-07-13",{"date":253,"type":34},"2026-05-06",{"date":255,"type":21},"2027-01",{"name":257,"class":258},"Becton, Dickinson and Company","INDUSTRY",4,{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":267,"enrollmentInfo":268,"targetDuration":4,"studyType":22,"phases":270,"briefSummary":271,"conditions":272,"keywords":275,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":64},"100622747","synchronized-core-pelvic-floor-activation-in-urinary-incontinence-100622747","NCT07387640","Synchronized Core-Pelvic Floor Activation in Urinary Incontinence","Synchronized Activation of Core and Pelvic Floor Muscles: A More Effective Strategy for Urinary Incontinence?","Inclusion Criteria:\n\n* Aged between 18 and 65 years\n* Diagnosed with stress, urge, or mixed urinary incontinence\n* Pelvic floor muscle strength grade ≥ 3 according to the Modified Oxford Scale\n* At least one episode of urinary leakage within the last month\n\nExclusion Criteria:\n\n* Pregnancy\n* Childbirth within the previous 6 weeks\n* Severe pelvic organ prolapse\n* Active vaginal or urinary tract infection\n* Presence of neurological or psychiatric disorders\n* Malignancy\n* Inability to cooperate with assessments or interventions","65 Years",{"count":269,"type":21},50,[52],"This study aims to investigate whether co-activation of the pelvic floor and core muscles improves treatment outcomes in individuals with urinary incontinence. Participants diagnosed with stress, or mixed urinary incontinence will undergo a 12-week pelvic floor physiotherapy program, with or without additional core muscle co-activation exercises. Changes in urinary incontinence severity, pelvic floor muscle function, core muscle activation, and quality of life will be evaluated.",[273,28,274,29],"Urinary Incontinence,Stress","Mixed Incontinence Due to Prolapse of Female Genital Organ",[276,277,278,279,280],"Pelvic floor muscle training","Core stability exercises","Core Muscle Co-activation","Pelvic floor physiotherapy","Surface Electromyography","2026-06-30",{"date":283,"type":34},"2026-07-01",{"date":285,"type":21},"2026-08-30",{"date":287,"type":21},"2027-08-30",{"name":289,"class":41},"Bezmialem Vakif University",{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":12,"sex":214,"minAge":18,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":22,"phases":297,"briefSummary":298,"conditions":299,"keywords":304,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":64},"100633265","improving-the-care-of-incontinence-associated-dermatitis-iad-using-a-beta-glucan-cream-as-a-hydrating-and-soothing-agent-100633265","NCT07524439","Improving the Care of Incontinence-Associated Dermatitis (IAD) Using a Beta-Glucan Cream as a Hydrating and Soothing Agent","Eligible participants are adults (≥18 years) with IAD secondary to urinary and\u002For fecal incontinence and an expected hospital stay of ≥7 days. Written informed consent will be obtained directly or via substitute decision-maker. Exclusion criteria include absence of IAD or incontinence, pediatric patients, and participants with known hypersensitivities to components of cream (e.g. beta-glucan).",{"count":137,"type":21},[52],"The goal of this clinical trial is to determine whether adding a β-glucan moisturizing cream to routine skin care can enhance skin healing, accelerate visible recovery, reduce discomfort, and improve both patient and clinician experiences. The study will also learn about the safety and tolerability of the β-glucan cream when used along with standard skin care.\n\nThe main questions it aims to answer are:\n\nAre there visible changes in the severity of IAD when β-glucan cream is added to standard care, and if so, to what extent does it reduce severity compared with standard care alone?\n\nDoes the β-glucan cream help IAD heal faster?\n\nDoes the cream reduce symptoms such as pain, itching, tingling, or burning?\n\nWhat medical problems or side effects, if any, do participants experience while using the β-glucan cream?\n\nResearchers will compare standard care plus β-glucan cream to standard care alone to see if the β-glucan cream provides additional benefit for treating IAD.\n\nParticipants will:\n\nReceive either β-glucan cream plus standard care or standard care alone\n\nHave the study cream applied once daily for up to 2 weeks\n\nHave their skin checked weekly by the study team using a standardized assessment tool\n\nAnswer questions about symptoms such as pain, itching, tingling, and burning\n\nAllow photographs of the affected skin area to be taken for secure clinical review\n\nBe monitored for any side effects or skin reactions during the study",[300,29,301,302,303],"Fecal Incontinence","Diaper Rash","Irritant Contact Dermatitis Caused by Faeces","Irritant Contact Dermatitis",[305,306],"Administration, Topical","Administration, Cutaneous","2026-06-23",{"date":309,"type":34},"2026-06-26",{"date":311,"type":34},"2026-05-01",{"date":313,"type":21},"2028-11-30",{"name":315,"class":41},"University of Alberta",{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":320,"acronym":321,"eligibilityCriteria":322,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":323,"enrollmentInfo":324,"targetDuration":4,"studyType":22,"phases":326,"briefSummary":327,"conditions":328,"keywords":329,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":64},"100538012","prospective-and-comparative-evaluation-of-a-medical-device-composed-of-a-perineal-probe-connected-to-a-mobile-application-in-the-management-of-stress-urinary-incontinence-100538012","NCT06285292","Prospective and Comparative Evaluation of a Medical Device Composed of a Perineal Probe Connected to a Mobile Application in the Management of Stress Urinary Incontinence.","PRIME","Inclusion Criteria:\n\n* Patients with moderate, severe or very severe stress urinary incontinence or mixed stress urinary incontinence (according to ICIQ-UI SF questionnaire score: moderate (6-12), severe (13-18) and very severe (19-21))\n* Patient aged between 18 and 60\n* Patient with a quality of life score measured with the I-QoL questionnaire less than or equal to 70 (score measured from 0 to 100, with poor quality of life: 0-35; average quality of life: 36-70; good quality of life: 71-100)\n* Not to have given birth in the last 6 months (to avoid post-partum physiological recovery)\n* Signed informed consent\n* Effective contraception throughout the study (declarative)\n* Patient must have a smartphone running at least Android 7 and iOS 12\n* Patient must be able to read and write French\n\nExclusion Criteria:\n\n* Patients with mild stress urinary incontinence or mixed stress urinary incontinence (ICIQ-UI SF score: mild (1-5))\n* Patient with a quality of life score above 70 (according to the I-QoL questionnaire: good quality of life: 71-100)\n* Patient undergoing other pelvic-perineal rehabilitation during the study period\n* Patients with neurological disease or congenital malformation, surgically or medically treated urinary incontinence or prolapse, perineal hypoesthesia or local conditions prohibiting the use of an intravaginal catheter\n* Infection of the bladder or vagina, or any symptoms associated with infection (itching, pain on urination or fever)\n* Contraindications to the use of the medical device\n* Anatomy making catheter placement difficult or impossible; in the case of prolapse, specialist advice is recommended.\n* Hemorrhage\n* Patients with genitourinary cancer (within the last 5 years)\n* Patients with extra-urethral \"incontinence\" (fistula, ectopic ureter)\n* Patients with severe urinary retention\n* Patient with vesico-ureteral reflux\n* Patients with hypoactive bladder\n* In case of peripheral denervation in the pelvic-perineal area, specialist advice is recommended\n* Patients wearing a sacral neuromodulation device\n* Patients in an exclusion period (determined by a previous or current study)\n* Impossibility of giving the subject clear information (subject in an emergency situation, difficulties in understanding the subject, etc.)\n* Patient under court protection\n* Patient under guardianship or curatorship\n* Pregnancy (positive pregnancy test)\n* Breastfeeding (as the hormonal impregnation caused by breastfeeding has a negative impact on perineal tone)\n* Use of Huawei and Oppo smartphones","60 Years",{"count":325,"type":21},138,[52],"Stress urinary incontinence (SUI) affects around 40% of women and has a major impact on quality of life. The gold standard for the treatment of SUI is pelvicfloor rehabilitation, but this presents constraints in terms of availability of healthcare professionals, as well as organization and travel for patients. Innovative devices offer self-training exercises for the pelvicfloor, thus promoting motivation and adherence to treatment. The hypothesis of this study is to prove that the use of a pelvicfloor medical device combined with 2 rehabilitation sessions is not inferior to pelvic-perineal rehabilitation.",[29],[330],"urinary incontinence, pelvic-floor muscles, pelvic-perineal rehabilitation",{"date":332,"type":34},"2026-06-25",{"date":334,"type":34},"2024-11-25",{"date":336,"type":21},"2026-11-25",{"name":338,"class":41},"Nantes University Hospital",{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":12,"sex":17,"minAge":346,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":22,"phases":349,"briefSummary":350,"conditions":351,"keywords":352,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":365},"100381567","adjustable-continence-therapy-act-for-the-treatment-of-female-sui-100381567","NCT04248283","Adjustable Continence Therapy (ACT) for the Treatment of Female SUI","A Clinical Investigation of the Adjustable Continence Therapy (ACT) for Female Stress Urinary Incontinence Due to Intrinsic Sphincter Deficiency","Inclusion Criteria:\n\n1. Female at least 22 years old\n2. Diagnosed with stress urinary incontinence with primary Intrinsic Sphincter Deficiency\n3. Provocative pad weight of greater than 11.0 grams\n4. Candidate for surgical intervention\n5. Negative urinalysis\n6. Normal cystourethroscopy\n7. Failed at least 6 months of previous treatment(s) for stress urinary incontinence (e.g., exercise regimen, electrical stimulation, surgical procedures, etc). Note: patients may have failed prior anti-incontinence procedures for SUI (e.g., suspension, sling, or urethral bulking agent)\n8. Willing and able to sign informed consent and comply with trial follow-up requirements\n\nExclusion Criteria:\n\n1. Pregnant or lactating\n2. Life expectancy of less than 5 years\n3. Has uncontrolled diabetes as evidenced by HbA1c over 6.5% and fasting plasma glucose over 130 mg\u002FdL\n4. Has auto-immune disease\n5. Undergoing radiation therapy\n6. Active urinary tract infection\n7. Detrusor instability refractory to medication\n8. Reduced bladder compliance as defined by a cystometrogram\n9. Significant residual volume (greater than 100 ml) after voiding in which detrusor contraction is weak, when the bladder volume is greater than or equal to 250 ml\n10. Has, had, or is suspected of having bladder cancer\n11. History of bladder stones\n12. Urethral stricture evidenced during cystourethroscopy\n13. Has a neurogenic bladder that is atonic or has detrusor sphincter dyssynergia\n14. Has a diathesis, hemophilia, or a bleeding disorder\n15. Has a rectocele, cystocele, urethrocele, enterocele, or pelvic prolapse of grade 3 or higher\n16. Had prior pelvic radiotherapy\n17. Had a prior artificial urinary sphincter implanted\n18. Has a neurogenic condition known to affect bladder\u002Fsphincter function","22 Years",{"count":348,"type":21},167,[52],"A prospective, single arm, non-randomized, multicenter, prospective case-series trial. The purpose of this trial is to demonstrate the safety and effectiveness of using the Adjustable Continence Therapy (ACT) to provide a clinically relevant improvement in stress urinary incontinence.",[29,273],[29,353,354,355,220],"Urination Disorders","Urination Involuntary","Urologic Diseases","2026-06-15",{"date":358,"type":34},"2026-06-17",{"date":360,"type":34},"2021-01-26",{"date":362,"type":21},"2032-05-31",{"name":364,"class":258},"Uromedica",5,{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":372,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":214,"minAge":4,"maxAge":4,"enrollmentInfo":374,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":376,"conditions":377,"keywords":380,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":64},"100368519","urinary-disorders-in-subacute-patients-after-stroke-100368519","NCT04078373","Urinary Disorders in Subacute Patients After Stroke","Assessment and Treatment of Urinary Disorders in Patients in the Subacute Phase After Stroke","UIMK","Inclusion Criteria:\n\n* subacute patients after ischaemic or hemorrhagic stroke;\n* direct transfer from acute hospital to complex inpatient rehabilitation at our Institute.\n\nExclusion Criteria:\n\n* incontinence before stroke;\n* previous brain injury or other brain disease;\n* previous bladder or prostate surgery;\n* inability to ambulate before stroke;\n* terminal disease with expected survival less than three months.",{"count":375,"type":21},250,"This observational study will address urinary disorders in subacute stroke patients. Patients without and with urinary disorders will be compared, and treatment outcome will be assessed among the latter.",[378,379,29],"Stroke, Ischemic","Stroke Hemorrhagic",[381,382,383,384],"stroke","inpatient rehabilitation","urinary disorders","treatment","2026-06-11",{"date":356,"type":34},{"date":388,"type":34},"2019-06-01",{"date":390,"type":21},"2026-10",{"name":392,"class":41},"University Rehabilitation Institute, Republic of Slovenia",{"id":394,"slug":395,"hasResults":12,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":399,"eligibilityCriteria":400,"healthyVolunteers":163,"sex":17,"minAge":401,"maxAge":402,"enrollmentInfo":403,"targetDuration":4,"studyType":22,"phases":405,"briefSummary":406,"conditions":407,"keywords":408,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":419,"locationsCount":64},"100642995","effects-of-a-multimodal-and-multidimensional-intervention-on-urinary-incontinence-in-young-nulliparous-female-athletes-100642995","NCT07644273","Effects of a Multimodal and Multidimensional Intervention on Urinary Incontinence in Young Nulliparous Female Athletes.","Effects of a Multimodal and Multidimensional Intervention on Urinary Incontinence in Young Nulliparous Female Athletes. Single-Center Randomized Controlled Stepped-Wedge Trial","PELVICATHLE","Inclusion Criteria :\n\n* Female subject, nulliparous\n* Member of an athletics club affiliated with the French Athletics Federation (FFA)\n* At least 15 years old at the start of the study and belonging to the U16\u002FU18\u002FU20\u002FU23 categories (born between January 1, 2005, and September 1, 2011)\n* Having internet access\n* Having access to a digital device (computer, tablet, mobile phone)\n* Affiliated with or covered by a social security scheme\n* Having freely given their express consent, as well as the express consent of both parents for minor participants\n\nExclusion Criteria :\n\n* Any individual deprived of their liberty or subject to legal protection (guardianship, curatorship, or protective supervision).\n* A pregnant woman, a woman who has been pregnant, or a woman planning a pregnancy within the last nine months.\n* Any individual unable to understand the purpose and conditions of the study.\n* Any individual unable to give their consent.","15 Years","40 Years",{"count":404,"type":21},198,[52],"A prevalence of urinary incontinence ranging from 5.7% to 80% has been observed in young nulliparous athletes during their activity.\n\nThe usual recommendations for managing adult women do not seem to be transferable.\n\nYoung nulliparous athletes need specific educational and behavioral interventions and an alternative to pelvic floor muscle strengthening.\n\nA multimodal and multidimensional intervention for athletes and coaches combining specific pelvic health education and strengthening of lumbopelvic-abdominal stability appears to be an innovative and optimal solution for reducing the symptoms of urinary incontinence in young nulliparous women who participate in athletics.",[29],[409,410,411],"Urinary incontinence","women's health","track and field","2026-06-08",{"date":414,"type":34},"2026-06-12",{"date":416,"type":21},"2026-09",{"date":418,"type":21},"2027-06",{"name":420,"class":41},"Centre Hospitalier Universitaire de Saint Etienne",{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":163,"sex":73,"minAge":18,"maxAge":323,"enrollmentInfo":428,"targetDuration":4,"studyType":22,"phases":429,"briefSummary":430,"conditions":431,"keywords":433,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":446,"locationsCount":4},"100627682","male-pelvic-floor-muscle-rehabilitation-exercises-100627682","NCT07451808","Male Pelvic Floor Muscle Rehabilitation Exercises","Male Pelvic Floor Muscle Rehabilitation (Kegel Exercises) Pelvic Floor Muscle Training","Inclusion Criteria:\n\n* Men 18 - 60 years of age\n* Must be able to achieve an erection\n\nExclusion Criteria:\n\n* Underlying medical conditions or poor health\n* Men who fall within the obese category based on standard body mass index (BMI) measurements",{"count":187,"type":21},[52],"Phase I\n\nG128 Study Objective\n\nThe ischiocavernosus (IC) and bulbospongiosus (BS) muscles are vital components of the superficial perineal layer, serving as the foundation for male sexual health and performance. These muscles play a primary role in achieving and maintaining erections by compressing the veins to trap blood within the erectile tissues. Furthermore, they are responsible for the rhythmic contractions necessary for ejaculation and the physiological sensations associated with orgasm.\n\nBeyond their role in sexual function, these muscles provide critical structural support to the pelvic floor and assist in urinary control. By working in tandem, the IC and BS muscles ensure penile rigidity while stabilizing the surrounding pelvic structures. Maintaining the strength and coordination of these muscles is essential for overall reproductive health and the prevention of pelvic floor dysfunction.\n\nThe primary objective of this clinical trial is to evaluate the clinical efficacy and therapeutic potential of Exercise G128 in strengthening the male pelvic floor musculature. Furthermore, the study aims to establish a comprehensive safety profile for Exercise G128 during active participation. The research seeks to address the following core investigative questions:\n\nTo what extent does Exercise G128 improve the tonicity and contractile strength of the IC and BS muscles?\n\nWhat is the incidence and nature of adverse medical events or physiological stressors reported by participants while performing the Exercise G128 protocol?\n\nResearchers will conduct a comparative analysis, benchmarking the physiological outcomes of Exercise G128 against existing clinical data regarding the efficacy of traditional Kegel exercises.\n\nParticipant Requirements:\n\nAdhere to a structured regimen, performing Exercise G128 four times weekly over a one-month intervention period.\n\nAttend bi-weekly telehealth consultations via video conferencing for supervised clinical assessments, progress monitoring, and physiological testing.\n\nMaintain a detailed daily log documenting functional progress, as well as any instances of physical exertion or soreness that necessitated a temporary cessation of the exercise protocol.",[80,29,432],"Premature Ejaculation",[434,196,435,436,437,438,439],"Dripping or leakage","Kegel exercises for men","ischiocavernosus muscle","bulbospongiosus muscle","Erectile dysfunction (ED)","Premature ejaculation","2026-06-07",{"date":442,"type":34},"2026-06-10",{"date":444,"type":21},"2026-12",{"date":61,"type":21},{"name":447,"class":41},"Dream Video LLC",{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":454,"eligibilityCriteria":455,"healthyVolunteers":12,"sex":17,"minAge":456,"maxAge":4,"enrollmentInfo":457,"targetDuration":4,"studyType":22,"phases":459,"briefSummary":460,"conditions":461,"keywords":463,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":476},"100552987","trial-of-transurethral-bulking-agent-injection-versus-single-incision-sling-for-stress-urinary-incontinence-100552987","NCT06480227","Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence","A Randomized Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence","BASIS","Inclusion Criteria:\n\n* Women ≥ 21 years\n* For \\> 3 months, bothersome SUI (response of somewhat, moderately, or quite a bit) without UUI or stress-predominant MUI. For those with equal bother of UUI and SUI, clinician determination that SUI is more severe\u002Fsignificant than UUI is required.\n* A positive cough stress test on standardized non-invasive testing or urodynamic SUI within the past 18 months.\n* Normal PVR \\\u003C 150 mL\n* Candidate for either study procedure as determined by treating surgeon\n* Available for up to 3 years.\n* Agrees to randomization.\n\nExclusion Criteria:\n\n* Anterior\u002Fapical vaginal prolapse beyond the hymen (\\>0 on POPQ)\n* Urge-predominant mixed UI despite stable therapy\n* Advanced UUI\u002FOAB 3rd line therapy treatment within 1 year of enrollment.\n* Planned hysterectomy, urethral or anterior\u002Fapical surgeries s requiring general anesthesia at the time of SUI treatment, during the last 6 months, or planned within the next 12 months.\n* Malignancy or history of radiation of the pelvis\n* Pregnant, post-partum, breast feeding or plans for pregnancy within 1 year\n* Incomplete emptying (PVR \\> 150mL)\n* Prior anti-incontinence procedure\n* Neurogenic bladder\n* Unwilling to continue current UUI treatment until completion of primary outcome at 12 months\n* Prior adverse reaction to synthetic mesh or urethral bulking material\n* Chronic bladder or pelvic pain conditions (e.g., Interstitial cystitis, painful bladder syndrome, fibromyalgia, chronic pelvic pain, etc.)\n* Active treatment for SUI with a pessary. For those using a pessary or other SUI support device, a 3-week washout period should occur prior to assessing baseline measures.","21 Years",{"count":458,"type":21},358,[52],"This is a multicentered, double-blind, randomized controlled, surgical trial of 358 women with inadequate symptom relief of stress urinary incontinence (SUI) or stress predominant mixed urinary incontinence (MUI) after conservative care.\n\nThe Primary Aim is to determine the comparative effectiveness (as defined by \"much\" or \"very much\" better on PGI-I) of transurethral bulking agent (TBA) \\[for 1 or 2 injections in 12 months\\] vs. single-incision sling (SIS) 12 months after treatment intervention in women with predominant stress urinary incontinence (SUI).",[28,29,462],"Mixed Urinary Incontinence",[29,464,465,466],"Pelvic Floor Disorders","Single Incision Sling","Transurethral Bulking Agent","2026-06-04",{"date":412,"type":34},{"date":470,"type":34},"2024-08-28",{"date":472,"type":21},"2030-12-31",{"name":474,"class":475},"NICHD Pelvic Floor Disorders Network","NETWORK",7,{"id":478,"slug":479,"hasResults":12,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":4,"eligibilityCriteria":483,"healthyVolunteers":12,"sex":73,"minAge":18,"maxAge":484,"enrollmentInfo":485,"targetDuration":4,"studyType":22,"phases":487,"briefSummary":490,"conditions":491,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":64},"100506789","phase-2-examining-the-effects-of-intra-detrusor-botox-at-time-of-holep-in-men-with-overactive-bladder-symptoms-100506789","NCT05878951","Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms","A Multicenter Randomized Controlled Trial Examining the Effects of Intra-detrusor Botulinum Toxin at Time of Holmium Laser Enucleation of the Prostate (HoLEP) in Men With Overactive Bladder (OAB) Symptoms","Inclusion Criteria:\n\n* Males 18 -89 undergoing HoLEP\n* Component of OAB symptoms including frequency, nocturia, urgency, and\u002For urge related incontinence\n* Willing to sign the Informed Consent Form\n* Able to read, understand, and complete patient questionnaires.\n\nExclusion Criteria:\n\n* Allergy or hypersensitivity to OnabotulinumtoxinA injections\n* Patients having a concurrent ureteroscopy +\u002F- laser lithotripsy, percutaneous nephrolithotomy, or non-urologic surgery at the time of their HoLEP\n* Anticipated need for perineal urethrostomy at the time of HoLEP\n* Prior pelvic radiation or patients with a history of bladder cancer with or without BCG therapy\n* Patients who lack decisional capacity\n* Active urinary tract infection","89 Years",{"count":486,"type":21},66,[488,489],"PHASE2","PHASE3","The objective of our multi-center randomized single-blind study is to examine the safety and effect of intra-detrusor OnabotulinumtoxinA injections at the time of holium laser enucleation of the prostate (HoLEP) in men with overactive bladder symptoms with and without urge incontinence.",[29,168,492,355],"Overactive Bladder","2026-06-02",{"date":467,"type":34},{"date":496,"type":34},"2023-07-13",{"date":498,"type":21},"2026-12-31",{"name":500,"class":41},"Northwestern University",{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":507,"eligibilityCriteria":508,"healthyVolunteers":163,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":509,"targetDuration":4,"studyType":22,"phases":511,"briefSummary":512,"conditions":513,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":42},"100626071","the-recover-study---postpartum-recovery-of-pelvic-floor-structures-and-the-impact-of-early-rehabilitation-100626071","NCT07430865","The RECOVER Study - Postpartum Recovery of Pelvic Floor Structures and the Impact of Early Rehabilitation","The RECOVER Study - Recovery of Pelvic Floor Structure and Function After Vaginal Childbirth- a Longitudinal Cohort Study With an Embedded Pilot Trial","RECOVER","Inclusion Criteria:\n\n* Individuals (over 18 years) who delivered a single child vaginally between 37 and 41 weeks of gestation, with a birthweight of at least 2500 grams.\n\nExclusion Criteria:\n\n* Delivered via c-section\n* Multiparous with previous third- or fourth-degree tears\n* History of major urogynecological surgery\n* Known neurological disorder (e.g., stroke, multiple sclerosis) that could affect the assessment outcomes\n* Severe connective tissue disorders that could affect the assessment outcomes\n* New pregnancy of more than 6 weeks during the study period\n* Pain with vaginal penetration, tampon use, or gynecological examinations that would prevent participation in assessments\n* Visible signs for wound complications assessed via REEDA tool (redness, oedema, ecchymosis, discharge, approximation) will exclude the participants from the first ultrasound assessment and vaginal palpation.",{"count":510,"type":21},380,[52],"The goal of this observational study with an embedded pilot clinical trial is to learn how the pelvic floor recovers after vaginal childbirth and whether early individualized pelvic floor muscle training can improve recovery in people who experience pelvic floor symptoms after vaginal delivery. The main questions it aims to answer are:\n\n* How do pelvic floor muscles and surrounding tissues change and recover during the first year after vaginal childbirth?\n* How are these structural changes and their recovery related to urinary, bowel, and vaginal symptoms?\n* In participants with pelvic floor symptoms after vaginal childbirth, does early individualized pelvic floor muscle training improve symptoms and support structural recovery compared with usual care?\n\nResearchers will compare participants who receive the early pelvic floor muscle training to those receiving standard postpartum care to see if the training helps improve pelvic floor function and reduce symptoms.\n\nParticipants will:\n\nAttend clinic visits at six weeks, and six months after childbirth\n\nComplete questionnaires about urinary, bowel, and vaginal symptoms, as well as physical activity and quality of life at six weeks, and four, six months, and twelve months after childbirth\n\nUndergo clinical pelvic floor assessments, including vaginal palpation of muscle strength, tone, and perineal body stability\n\nHave ultrasound examinations of the pelvic floor to assess muscle structure, tissue integrity, and perineal body morphology\n\nFor those in the pilot trial, participate in an early, individualized pelvic floor muscle training program\n\nThis study will provide important information about how the pelvic floor heals after childbirth, how structural changes are linked to symptoms, and whether early personalized training can help prevent long-term problems.",[29,514,515,516,517,518,519,520],"Pelvic Organ Prolapse (POP)","Bowel Symptoms","Postpartum","Physiotherapy and Rehabilitation","Pelvic Floor Muscle Training","Pelvic Floor","Recovery","2026-05-21",{"date":523,"type":34},"2026-05-27",{"date":525,"type":34},"2026-04-07",{"date":527,"type":21},"2029-12-31",{"name":529,"class":530},"Vastra Gotaland Region","OTHER_GOV",{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":537,"eligibilityCriteria":538,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":539,"targetDuration":4,"studyType":22,"phases":541,"briefSummary":542,"conditions":543,"keywords":544,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":549,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":555,"locationsCount":64},"100609811","implementing-a-mobile-health-application-for-women-veterans-with-urinary-incontinence-myhealthebladder-function-queri-30-100609811","NCT07219433","Implementing a Mobile Health Application for Women Veterans With Urinary Incontinence (MyHealtheBladder): Function QUERI 3.0","Implementing a Mobile Health Application for Women Veterans With Urinary Incontinence: MyHealtheBladder in Function QUERI 3.0 (QUE 25-008)","MHB","Inclusion Criteria:\n\nSite Inclusion Criteria:\n\n* Facility is part of the U.S. Department of Veterans Affairs (VA) health system.\n* Clinic serves at least 100 Women Veterans annually.\n* Identified site champion (e.g., clinician or staff member) who is willing to assume required program responsibilities for implementation.\n\nPatient Inclusion Criteria:\n\n* Women Veterans\n* Have any type of Urinary Incontinence existing for at least 3 months\n\nExclusion Criteria:\n\nSite Exclusion Criteria:\n\n* Clinic has already implemented the MyHealtheBladder program.\n\nPatient Exclusion Criteria:\n\n* No access to computer or mobile device\n* No email account\n* Institutionalized",{"count":540,"type":21},20,[52],"Implementing a Mobile Health Application for Women Veterans with Urinary Incontinence (MyHealtheBladder): Function QUERI 3.0 aims to compare implementation approaches while also gathering information on clinical effects of the Evidence-Based Program (EBP) in its new context and focusing on equitable reach (extent to which the program serves all members of its intended audience). The overall goal is to implement, evaluate, and sustain MyHealtheBladder in 20 VA facilities using a type III effectiveness-implementation hybrid study framework and parallel cluster randomized trial (CRT) design.",[29],[545,546,547,109,548],"Veterans","Implementation Science","Functional Status","Mobile Applications",{"date":550,"type":34},"2026-05-22",{"date":552,"type":34},"2026-04-30",{"date":554,"type":21},"2030-09-30",{"name":556,"class":557},"VA Office of Research and Development","FED",{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":563,"acronym":4,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":214,"minAge":4,"maxAge":4,"enrollmentInfo":565,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":567,"conditions":568,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":573,"lastUpdatePostDateStruct":574,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":580,"locationsCount":365},"100541933","nxt-post-market-clinical-follow-up-100541933","NCT06336304","NXT Post-Market Clinical Follow-up","NXT Urodynamics System Post-Market Clinical Follow-up Clinical Investigation","Inclusion Criteria:\n\n* Patients medically indicated for urodynamic study\n* Patient or legally authorized representative provides written authorization and\u002For consent per institution and geographical requirements\n\nExclusion Criteria:\n\n* Patients or legally authorized representative with cognitive or psychiatric condition that interferes with or precludes direct and accurate communication regarding the study, giving informed consent or ability to complete the patient questionnaire\n* Patients with confirmed active bladder infections (not including patients with asymptotic bacteria)\n* Pregnant women\n* Patients with recent (less than 2 weeks) pelvic floor surgery\n* Requires use of suprapubic catheter",{"count":566,"type":21},180,"NXT Urodynamics System Post-Market Clinical Follow-up Clinical Investigation to Confirm Ongoing Safety and Performance in Urodynamic Patient Sub-Populations",[29,569,570,571,572],"Urinary Obstruction","Urinary Bladder, Overactive","Urinary Bladder, Neurogenic","Urinary Incontinence, Urge","2026-05-13",{"date":575,"type":34},"2026-05-15",{"date":577,"type":34},"2024-06-18",{"date":579,"type":21},"2027-03",{"name":581,"class":258},"Laborie Medical Technologies Inc.",{"id":583,"slug":584,"hasResults":12,"nctId":585,"briefTitle":586,"officialTitle":587,"acronym":588,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":590,"targetDuration":4,"studyType":22,"phases":591,"briefSummary":592,"conditions":593,"keywords":597,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":607,"locationsCount":64},"100544518","tens-analgesia-during-outpatient-urethral-bulking-for-stress-urinary-incontinence-100544518","NCT06369922","TENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence.","Transcutaneous Electrical Nerve Stimulation Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence.","TENSUB","Inclusion Criteria:\n\n* • Women, Age ≥18 years\n\n  * Diagnosis of SUI\n  * Scheduled to undergo transurethral bulking in the office\n  * Able to read\u002Fwrite English\n\nExclusion Criteria:\n\n* • Cutaneous damage such as ulcers or broken skin on target treatment area\n\n  * Currently implanted cardiac pacemaker or defibrillator\n  * Pre-procedural use of opioids for pain management, less than 8 hours from last dose\n  * Participants with altered sensation below the umbilicus",{"count":187,"type":21},[52],"This will be a double-blind randomized control trial in women with stress urinary incontinence who are undergoing an outpatient transurethral bulking procedure for stress urinary incontinence. Subjects will be identified by the University of Rochester urologists and urogynecologists participating in the study who currently oversee stress incontinence care. Subjects will be randomized into two groups. One group will be undergoing the cystoscopy with transcutaneous electrical nerve stimulation (TENS) for analgesia, and the second group will have the cystoscopy with placebo TENS.",[594,29,273,595,596],"Stress Incontinence Female","Pain","Pain Acute",[598,599,600],"TENS","pain","Transcutaneous Electrical Nerve Stimulation Analgesia","2026-05-11",{"date":573,"type":34},{"date":604,"type":34},"2024-07-01",{"date":606,"type":21},"2027-06-01",{"name":608,"class":41},"University of Rochester",{"id":610,"slug":611,"hasResults":12,"nctId":612,"briefTitle":613,"officialTitle":614,"acronym":4,"eligibilityCriteria":615,"healthyVolunteers":163,"sex":17,"minAge":616,"maxAge":617,"enrollmentInfo":618,"targetDuration":4,"studyType":22,"phases":620,"briefSummary":621,"conditions":622,"keywords":623,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":627,"lastUpdatePostDateStruct":628,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":633,"locationsCount":64},"100637268","effects-of-paula-exercises-and-tibial-nerve-stimulation-in-stress-urinary-incontinence-100637268","NCT07576205","Effects of Paula Exercises and Tibial Nerve Stimulation in Stress Urinary Incontinence","Combine Effects of Paula Exercises and Tibial Nerve Stimulation on Incontinence, Pelvic Floor Muscles Strength, Sexual Function and Quality of Life in Stress Urinary Incontinence","Inclusion Criteria:\n\n* Multiparous women (≥2 full-term vaginal deliveries)\n* Clinical diagnosis of stress urinary incontinence (confirmed by cough stress test)\n* Duration of symptoms ≥3 months\n* Ability to correctly perform pelvic floor contractions (confirmed by digital examination)\n\nExclusion Criteria:\n\n* Neurological disorders (e.g., multiple sclerosis, spinal cord injury)\n* Mixed or urge urinary incontinence as the predominant type\n* Previous pelvic surgery or incontinence-related procedures within the past year\n* Current pregnancy or \\\u003C6 months postpartum\n* Pelvic organ prolapse beyond stage II (POP-Q system)\n* Current use of other incontinence therapies (e.g., medication, PTNS, PFMT)\n* Diagnosed malignancy\n* Diagnosed psychiatric disorder\n* Pregnancy\n* Diagnosed dermatological condition\n* Participants who are currently enrolled in other clinical trials to avoid potential confounding factors.","30 Years","45 Years",{"count":619,"type":21},52,[52],"The aim of this study is to compare the combined effects of Paula method \\& tibial nerve stimulation on incontinence, pelvic floor muscles strength, sexual function and quality of life in stress urinary incontinence",[29],[624,625,519,116,626,28],"Tibial Nerve","Incontinence","Female","2026-05-04",{"date":629,"type":34},"2026-05-08",{"date":631,"type":34},"2025-10-01",{"date":283,"type":21},{"name":634,"class":41},"Riphah International University",{"id":636,"slug":637,"hasResults":12,"nctId":638,"briefTitle":639,"officialTitle":640,"acronym":4,"eligibilityCriteria":641,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":642,"enrollmentInfo":643,"targetDuration":4,"studyType":22,"phases":645,"briefSummary":647,"conditions":648,"keywords":649,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":651,"lastUpdatePostDateStruct":652,"startDateStruct":654,"completionDateStruct":656,"leadSponsor":657,"locationsCount":64},"100205612","phase-1-muscle-fiber-fragment-treatment-for-urinary-incontinence-100205612","NCT01953263","Muscle Fiber Fragment Treatment for Urinary Incontinence","A Phase 1 Study of Human Muscle Fiber Fragment (MFF) Treatment for Urinary Incontinence","Inclusion Criteria:\n\n* Adult female patients who are not pregnant or lactating\u002Fbreast-feeding and must be either not sexually active, surgically sterilized, or must be practicing an effective method of birth control as determined by the investigator\n* Patients between the ages of 18 and 75 years\n* Patients with positive diagnosis of urinary incontinence due to sphincter insufficiency caused by acquired (e.g., stress urinary incontinence) and\u002For congenital conditions.\n* Patients with cystometric capacity of bladder \\> 100 ml\n* Patients with normal renal function\n* Patients with a history of primary incontinence\n\nExclusion Criteria:\n\n* Patients with a history of hypercontractile bladder, non-compliant bladder, hydronephrosis or neurogenic bladder\n* Patients with an active urinary tract infection as evidenced by positive urine culture\n* Patients who are taking medication that affect urination such as prescription drugs, over-the-counter drugs, or dietary supplements, including herbal supplements and those taken with teas\n* Patients requiring concomitant use of or treatment with immunosuppressive agents\n* Patients with a history of systemic conditions, including but not limited to HIV, diabetes and chronic liver disease (including Hepatitis B or C), that the Investigator believes may jeopardize the safety of the patient to participate in the study\n* Patients with evidence or diagnosis of any primary muscle disease or coagulation disorder (including concomitant anti-coagulation therapy)\n* Patients who have been treated with any other investigational drug or participated in any investigational study within 30 days prior to enrollment in this study\n* Patients who have been treated with any cellular therapy within 12 months prior to enrollment in this study\n* Patients with urinary incontinence other than the categories being investigated\n* Patients with significant (\\>grade 2) pelvic organ prolapse\n* Patients with vaginal prolapse beyond introitus\n* Patients with neurological disorders\n* Patients with abnormal bladder capacity (i.e., less than 100 cc)\n* Patients with abnormal urologic conditions, including post-void residual, urethral stricture and bladder neck contracture, spastic bladder, vesicoureteral reflux, bladder stones, bladder tumors, hydronephrosis, other renal impairment","75 Years",{"count":644,"type":21},10,[646,488],"PHASE1","This study is designed to evaluate the safety of autologous muscle fiber fragments for the treatment of urinary incontinence due to incompetent outlet (bladder neck\u002Furethra).",[29],[650],"urinary incontinence, muscle fibers","2026-04-22",{"date":653,"type":34},"2026-04-23",{"date":655,"type":4},"2016-01",{"date":38,"type":21},{"name":658,"class":41},"Wake Forest University",{"id":660,"slug":661,"hasResults":12,"nctId":662,"briefTitle":663,"officialTitle":664,"acronym":4,"eligibilityCriteria":665,"healthyVolunteers":163,"sex":214,"minAge":666,"maxAge":103,"enrollmentInfo":667,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":669,"conditions":670,"keywords":675,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":680,"lastUpdatePostDateStruct":681,"startDateStruct":683,"completionDateStruct":685,"leadSponsor":687,"locationsCount":259},"100634125","the-voided-urinary-perineal-and-faecal-microbiota-among-children-and-adolescents---the-ppuf-study-100634125","NCT07535619","The Voided Urinary, Perineal, and Faecal Microbiota Among Children and Adolescents - the PpUF-study.","The Voided Urinary, Perineal, and Faecal Microbiota Among Children and Adolescents With Overactive Bladder and Daytime Urinary Incontinence and Healthy Children and Adolescents - the PpUF-study.","Inclusion Criteria:\n\n* Overactive bladder as per International Children's Continence Society criteria (cases only).\n* At least two wet days per week (cases only).\n* No prior pharmacological treatment of OAB and DUI (cases only).\n* No lower urinary tract symptoms (healthy participants only).\n* Negative urine dipstick test\n\nExclusion Criteria:\n\n* No known urogenital abnormality affecting the lower urinary tract function.\n* No known gastrointestinal or neurological diseases.\n* No use of systemic drugs within five half-lives of the drug.\n* No use of systemic antibiotics within three months before inclusion\n* No current urinary tract infection.\n* No urinary tract infection within the last three months prior to inclusion.\n* No current constipation.\n* Abnormal uroflowmetry (healthy participants only).","5 Years",{"count":668,"type":21},110,"The aim of this study is to investigate whether the voided urinary, perineal\u002Fpreputial, and the fecal microbiota are different between children suffering from Overactive Bladder (OAB) and Daytime Urinary Incontinence (DUI) compared to age- and gender-matched healthy children without bladder symptoms. Moreover, the study aims to investigate if the microbiota is different according to the severity of DUI and if the microbiota is changed throughout treatment of DUI. A follow-up study will as well be performed on healthy children to investigate how the microbiota evolves with increasing age and pubertal stage. Children with OAB and DUI will be recruited from involved pediatric departments, and specimen in the form of urine, perineal\u002Fpreputial swabs, and feces will be collected according to the protocol.",[29,671,353,355,220,672,673,674],"Daytime Wetting","Urological Manifestations","Elimination Disorders","Behavioral Symptoms",[676,677,678,679],"Voided Urinary Microbiota","Perineal Microbiota","Fecal Microbiota","Illumina MiSeq Sequencing","2026-04-15",{"date":682,"type":34},"2026-04-17",{"date":684,"type":34},"2022-12-14",{"date":686,"type":21},"2028-06",{"name":688,"class":41},"Aalborg University Hospital"]